Search results
Results from the WOW.Com Content Network
In June 2020, octreotide (Mycapssa) was approved for medical use in the United States with an indication for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. [13] [6] Mycapssa is the first oral somatostatin analog (SSA) approved by the FDA. [6]
Medications typically include octreotide or, if not available, vasopressin and nitroglycerin to reduce portal venous pressures. [13] Terlipressin appears to be more effective than octreotide, but it is not available in many areas of the world. [16] [30] It is the only medication that has been shown to reduce mortality in acute variceal bleeding ...
Octreotate or octreotide acid is a somatostatin analogue that is closely related to octreotide. Its amino acid sequence is H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-OH while octreotide has the terminal threonine reduced to the corresponding amino alcohol.
An octreotide scan is a type of SPECT scintigraphy used to find carcinoid, pancreatic neuroendocrine tumors, and to localize sarcoidosis. It is also called somatostatin receptor scintigraphy (SRS). Octreotide , a drug similar to somatostatin , is radiolabeled with indium-111 , [ 1 ] and is injected into a vein and travels through the bloodstream.
Lanreotide, sold under the brand name Somatuline among others, is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analogue of somatostatin, like octreotide. Lanreotide (as lanreotide acetate) is manufactured by Ipsen.
The selection and use of essential medicines. Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. 2015. hdl: 10665/189763. ISBN 978-92-4-069494-1. ISSN 0512-3054. WHO technical report series; no. 994.
The natural somatostatin receptor ligand, the 14 amino acid peptide somatostatin (A), was abridged to the biologically more stable 8 amino acid peptide Octreotide (OC, B). Introduction of a tyrosine into the 3rd position of the Octreotide sequence resulted in Tyr3-Octreotide (TOC, C), which allows for iodination of the tyrosine residue with the ...
Edotreotide (USAN, also known as (DOTA 0-Phe 1-Tyr 3) octreotide, DOTA-TOC, DOTATOC) is a substance which, when bound to various radionuclides, is used in the treatment and diagnosis of certain types of cancer. [3] When used therapeutically it is an example of peptide receptor radionuclide therapy.